University of Groningen
Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory
bowel disease
Buurman, Dorien Joke
DOI:
10.33612/diss.98535663
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Buurman, D. J. (2019). Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.98535663
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Complications and optimalisation of
Mesalazine and anti-TNF-alpha therapy in
D.J. Buurman
Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease
ISBN: 978-94-034-1928-2
ISBN: 978-94-034-1929-9 (Electronic version)
Cover design: Helga de Graaf, Studio Eye Candy Cover artwork: Mount Fuji, Katsushika Hokusai (1760–1849) Layout: Helga de Graaf, Studio Eye Candy
Printed by Ipskamp Printing
This thesis was financially supported by the Graduate School of Medical Sciences.
Copyright © 2019 D.J. Buurman
All right reserved. No part of this thesis may be reproduced ,stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.
Complications and optimalisation of
Mesalazine and anti-TNF-alpha therapy in
inflammatory bowel disease
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 6 november 2019 om 16.15 uur
door
Dorien Joke Buurman
geboren op 4 oktober 1983 te Emmen
Promotores
Prof. dr. G. Dijkstra Prof. dr. R.K. Weersma
Beoordelingscommissie
Prof. dr. H.J. Verkade Prof. dr. C.J. van der Woude Prof. dr. C.Y. Ponsioen
Paranimfen
S.T. Buurman S. Baas-Brunen
Table of contents
Chapter 1 Introduction
Part I: Mesalazine
Chapter 2 Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study Scan J Gastroenterology 2015 Apr; 50(4): 399-405
Chapter 3 Mesalazine luxated auto-immune hepatitis/small duct PSC overlap syndrome in an ulcerative colitis patient: case report and review of literature
Submitted
Chapter 4 Clinical Features and HLA association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel disease J Crohns Colitis 2016 Feb;10(2):149-58
Part II: Anti-TNF-alpha
Chapter 5 Detection of infliximab levels and anti-infliximab antibodies: a Comparison of three different assays
Aliment Pharmacol Ther 2012;36:765-771
Chapter 5a Letter: Detection of infliximab levels and anti-infliximab antibodies: a Comparison of three different assays – authors’reply
Aliment Pharmacol Ther, 2013 Jan;37(2):282
Chapter 6 Quantitative comparison of the neutralizing capacity, immunogenicity and cross reactivity of anti-TNF-alpha biologicals and an Infliximab-biosimilar
Plos One 2018 Dec 11;13(12)
9 23 37 47 69 81 85
Chapter 7 Immunogenicity to anti-TNF alpha: a non-HLA association Manuscript in preparation
Chapter 8 Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice
Aliment Pharmacol Therapy 2015 sep; 42(5):529-39
Chapter 8a Letter: infliximab therapy for patients with inflammatory bowel disease: some unanswered questions - author’s reply
Aliment Pharmacol Ther 2015 Nov;42(9):1134
Chapter 9 Colopulse tablets perform comparably in healthy volunteers and Crohns’s patients and show no influence of food and time of food intake on bioavailability
J Control Release 2013, Dec 28;172(3):619-24
Chapter 10 Towards Mucosal Application of Infliximab in the Therapy of Enterocolitis (TOMATE) : a proof of concept study
Study protocol
Chapter 11 Summary, discussion and future perspectives
Addendum Samenvatting Dankwoord Curriculum vitae Bibliography 99 113 132 137 155 175 188 192 195 197
